Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private PlacementGlobeNewsWire • 08/05/22
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/02/22
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022GlobeNewsWire • 07/29/22
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart FailureGlobeNewsWire • 07/27/22
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic NeuropathyGlobeNewsWire • 06/29/22
Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare ConferenceGlobeNewsWire • 06/01/22
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart FailureGlobeNewsWire • 05/31/22
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical UpdateGlobeNewsWire • 05/05/22
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022GlobeNewsWire • 04/29/22
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)GlobeNewsWire • 04/02/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lexicon Pharmaceuticals, Inc. - LXRXPRNewsWire • 03/26/22
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)GlobeNewsWire • 03/21/22
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of SotagliflozinGlobeNewsWire • 03/17/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of InvestorsBusiness Wire • 03/09/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of InvestorsBusiness Wire • 03/09/22
The Law Offices of Frank R. Cruz Announces Investigation of Lexicon Pharmaceuticals, Inc. (LXRX) on Behalf of InvestorsBusiness Wire • 03/08/22
Lexicon Pharmaceuticals, Inc.'s (LXRX) CEO Lonnel Coats on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/28/22
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical UpdateGlobeNewsWire • 02/28/22